Ponatinib: A Review of the History of Medicinal Chemistry behind Its Development
Mayara Nascimento,Stefany Moura,Lidia Parra,Valeska Vasconcellos,Gabriela Costa,Debora Leite,Maria Dias,Tácio Fernandes,Lucas Hoelz,Luiz Pimentel,Monica Bastos,Nubia Boechat
DOI: https://doi.org/10.3390/ph17101361
IF: 4.6
2024-10-12
Pharmaceuticals
Abstract:The primary treatment for chronic myeloid leukemia (CML) involves first- and second-generation tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, bosutinib, and dasatinib. However, these medications are ineffective against mutations in the kinase domain of the ABL1 protein, particularly in the protein with the T315I mutation. To address this, ponatinib (PNT), a third-generation inhibitor, was developed. Despite its efficacy in treating the BCR-ABL1T315I mutation, the use of PNT was briefly suspended in 2013 due to serious adverse effects but was subsequently reintroduced to the market. During the drug discovery and development process, it is rare to consolidate all information into a single article, as is the case with ponatinib. This review aims to compile and chronologically organize the research on the discovery of ponatinib using medicinal chemistry tools and computational methods. It includes in silico calculations, such as the octanol/water partition coefficient (cLogP) via SwissAdme, and 2D maps of intermolecular interactions through molecular docking. This approach enhances understanding for both specialists and those interested in medicinal chemistry and pharmacology, while also contextualizing future directions for further optimizations of ponatinib, facilitating the development of new analogs of this crucial inhibitor for the treatment of CML and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).
pharmacology & pharmacy,chemistry, medicinal